<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04545099</url>
  </required_header>
  <id_info>
    <org_study_id>4-2020-0804</org_study_id>
    <nct_id>NCT04545099</nct_id>
  </id_info>
  <brief_title>Comparison of the Impacts of Sugammadex With Neostigmine on Patency of Laryngeal Opening (Glottic Aperture Angle)</brief_title>
  <official_title>Comparison of the Impacts of Sugammadex With Neostigmine on Patency of Laryngeal Opening (Glottic Aperture Angle)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the degree of change in the angle of the vocal cords&#xD;
      before and after administration of neostigmine or sugammadex. Moreover, we intend to compare&#xD;
      the angle of vocal folds after administration of neostigmine or sugammadex.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>triple (Participant, Care Provider, investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Angle of vocal folds after administration of sugammadex or neostigmine 2) Degree of change in angle of vocal folds before and after administration of sugammadex or neostigmine</measure>
    <time_frame>1-2 minutes after drug administration (inhalation, exhalation)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of change in angle of vocal folds before and after administration of sugammadex or neostigmine</measure>
    <time_frame>1) Just before drug administration 2) 1-2 minutes after drug administration (inhalation, exhalation)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recover from spontaneous breathing</measure>
    <time_frame>immediately after drug(sugammadex or neostigmine) administration</time_frame>
    <description>Time taken to recover from spontaneous breathing(6ml/kg or more) after administration of sugammadex or neostigmine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to extubation</measure>
    <time_frame>immediately after drug(sugammadex or neostigmine) administration</time_frame>
    <description>Time taken to extubation after administration of sugammadex or neostigmine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Supraglottic Airway Device Insertion</condition>
  <arm_group>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Sugammadex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of Neostigmine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Administration of Sugammadex for muscle relaxation reversal</description>
    <arm_group_label>Sugammadex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Administration of Neostigmine for muscle relaxation reversal</description>
    <arm_group_label>Neostigmine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Adult patients who undergoes elective surgery under general anesthesia with supraglottic&#xD;
        airway device.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients under 20 years old&#xD;
&#xD;
          2. Pregnant women&#xD;
&#xD;
          3. Patients who can not read the consent form or are not fluent in Korean (illiterate,&#xD;
             foreigner)&#xD;
&#xD;
          4. Patients who refused the clinical trial&#xD;
&#xD;
          5. Patients with dementia or cognitive impairment&#xD;
&#xD;
          6. Patients with neuromuscular disorders impairing neuromuscular blockade&#xD;
&#xD;
          7. Renal dysfunction (estimated Glomerular Filtration Rate less than 30 ml/min/1.73m2)&#xD;
&#xD;
          8. Past history of allergic reactions to neostigmine or sugammadex&#xD;
&#xD;
          9. Patients with ASA class IV or higher&#xD;
&#xD;
         10. Robotic surgery, adenoid or tonsillectomy&#xD;
&#xD;
         11. Patients with moderate or severe asthma, pulmonary function tests with forced&#xD;
             expiratory volume for 1second of 1 liter or less, patients with upper respiratory&#xD;
             infection symptoms within 2 weeks before surgery, current smokers (within 1 month of&#xD;
             smoking cessation is included.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-Rim Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeong-Rim Lee</last_name>
    <phone>82-2-2224-4135</phone>
    <email>MANYA@yuhs.ac</email>
  </overall_contact>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

